In The News,

Payer Workshops on Clinical Endpoints and P&R for Novel Biologic

For a novel biologic, ADVI collaboratively designed, meticulously planned and moderate 1.5 days of EU and US payer workshops, gaining responses to and general consensus of a target product profile that includes P&R needs and expectations; label, including primary and secondary clinical endpoint evaluations; and outcomes data requirements.